Seeking Alpha

Array BioPharma (ARRY) up 25.8% AH as it signs a deal worth up to $467M ($45M up front and $422M...

Array BioPharma (ARRY) up 25.8% AH as it signs a deal worth up to $467M ($45M up front and $422M in milestones) with Novartis (NVS) to license its experimental cancer drug candidates.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|